Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data

PURPOSE: The treatment landscape for advanced, unresectable, or metastatic urothelial carcinoma (aUC) has shifted substantially since the advent of immune checkpoint inhibitors (ICIs). We investigated the extent to which pembrolizumab therapy is superior to conventional chemotherapy as a second-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyake, Makito, Nishimura, Nobutaka, Shimizu, Takuto, Ohnishi, Mikiko, Kuwada, Masaomi, Itami, Yoshitaka, Inoue, Takeshi, Ohnishi, Kenta, Matsumoto, Yoshihiro, Yoshida, Takanori, Tatsumi, Yoshihiro, Shinohara, Masatake, Hori, Shunta, Morizawa, Yosuke, Gotoh, Daisuke, Nakai, Yasushi, Anai, Satoshi, Torimoto, Kazumasa, Aoki, Katsuya, Fujii, Tomomi, Tanaka, Nobumichi, Fujimoto, Kiyohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858764/
https://www.ncbi.nlm.nih.gov/pubmed/35210859
http://dx.doi.org/10.2147/CMAR.S348899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858764/
https://www.ncbi.nlm.nih.gov/pubmed/35210859
http://dx.doi.org/10.2147/CMAR.S348899

Ejemplares similares